drugset

drugset / Trial / NCT00560703

Treatment of Patients With Blepharitis and Facial Rosacea

NCT00560703 ↗

Phase 2 Completed 70 enrolled Galderma R&D

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To determine the safety and efficacy of sub-antimicrobial dose COL-101 in the treatment of patients who have both blepharitis and facial rosacea

Timeline

Start: 2007-11
Primary completion: 2009-05
Completion: 2009-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	COL-101	Unknown	40 mg	—

Indications